Cellectar Reports Iopofosine I 131 Data in BTKi-Refractory Waldenström Macroglobulinemia
FLORHAM PARK, N.J. — September 29, 2026 Cellectar Biosciences announced that a subset analysis from the Phase 2 CLOVER-WaM...
Orphan Drug
Advertisement
Glycomine Gains FDA Breakthrough Status for GLM101
San Carlos, California, U.S., September 24, 2026 Glycomine, Inc. has announced that the U.S. Food and Drug Administration (FDA)...
Caliway Reports Positive Phase 2 Results for CBL-514 in Dercum
New Taipei City, Taiwan, September 22, 2026 Caliway Biopharmaceuticals has announced positive final results from its randomized, single-blind, placebo-controlled...
AIM Highlights Ampligen Potential in Pancreatic Cancer
OCALA, Fla. — September 22, 2026 AIM ImmunoTech Inc. highlighted the potential role of Ampligen® (rintatolimod) in pancreatic cancer...
Ophirex Publishes Phase 2 BRAVIO Varespladib Data
Durham, North Carolina — September 22, 2026 Ophirex announced publication of results from the Phase 2 BRAVIO clinical trial...
Advertisements
Arcturus to Present ARCT-810 Phase 2 OTC Deficiency Data
SAN DIEGO — September 18, 2026 Arcturus Therapeutics announced plans to provide an update on its ARCT-810 Phase 2...
Beacon Therapeutics Reports Positive VISTA Data for Laru-zova
LONDON and CAMBRIDGE, Mass September 21, 2026 — Beacon Therapeutics announced positive topline results from the pivotal VISTA trial...
Abbisko Therapeutics Reports Positive Phase 2 Lavengratinib Data
Shanghai, China, September 21, 2026 Abbisko Therapeutics has announced positive preliminary results from a Phase 2 clinical study evaluating...
MaaT Pharma Advances PHOENIX After Negative EMA Opinion
LYON, France — September 18, 2026 MaaT Pharma announced that the Committee for Medicinal Products for Human Use (CHMP)...
One04 Therapeutics Launches With CPV-104 Clinical Expansion
FREIBURG, Germany — September 15, 2026 One04 Therapeutics GmbH & Co. KG announced its launch as a clinical-stage biopharmaceutical...
Advertisement
